Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study…

Overview of attention for article published in Trials, April 2018

Altmetric Badge

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 38 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 14,439 followers.

RT @DrewMoghanaki: A clinic in South Korea launches a RCT of EBRT with SBRT boost for prostate cancer (18 v 21 Gy). #radonc #pcsm https://t…

Reply Repost Favourite

RT @DrewMoghanaki: A clinic in South Korea launches a RCT of EBRT with SBRT boost for prostate cancer (18 v 21 Gy). #radonc #pcsm https://t…

Reply Repost Favourite

Wow. Will be interested to see the PRO. https://t.co/RK5VbKQ27l

Reply Repost Favourite

A clinic in South Korea launches a RCT of EBRT with SBRT boost for prostate cancer (18 v 21 Gy). #radonc #pcsm https://t.co/n4cVTlGIwj https://t.co/BPNGvqxnWX

Reply Repost Favourite